Cellectar Biosciencesincis A Latestageclinical Biopharmaceutical Company Focused On Developing Targeted Cancer Therapies Using Its Proprietary Phospholipid Drug Conjugatea Cpdcplatformthecompany Aims To Improvetreatment Efficacy And Safety By Minimizing Off Target Effectsaddressing Significant Unmet Medical Needs In Oncology Cellectar S Pdc Technology Allows For Systematic Screening Of Drug Candidatesoptimizing Delivery To Hard To Treat Cancers Whilereducing Damageto Healthy Tissuesthecompany Has A Robust Product Pipelineincluding Iopofosinei 1 1Which Is In Phase2B Trials For Relapsed Refractory Multiplemyeloma And Cns Lymphomaand Clr 121225An Actinium 225 Based Therapy Targeting Solid Tumorscellectar Also Engages In Research Collaborations To Expand Its Pipelineand Acceleratedevelopment With A Team Of Industry Veteranscellectar Is Exploring Strategic Alternatives To Enhancegrowthfocusing On Markets With Limited Competition And Scalableopportunitiesthecompany Is Dedicated To Developing Therapies For Oncology Patients With High Unmet Needsparticularly Thoseeligiblefor Accelerated Regulatory Pathways
